J&J TECVAYLI DARZALEX FASPRO Survival Data Redefine Long-Term Outlook in Early Multiple Myeloma Relapse

J&J Tecvayli Darzalex Faspro survival data unveiled this week show that patients treated with the combination as early as second line for relapsed or refractory multiple myeloma (RRMM) may achieve a mortality risk and life expectancy close to that of the general population. The new findings come from model-based analyses of Johnson & Johnson’s Phase 3 MajesTEC-3 study, presented at the 2026 International Myeloma Society (IMS) Annual Meeting. Johnson & Johnson (NYSE: JNJ) announced the data on September 23, 2026, from Raritan, New Jersey, describing them as further evidence that TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), referred to in the analyses as Tec-Dara can meaningfully reshape long-term expectations for patients who relapse after one to three prior lines of therapy.

The J&J Tecvayli Darzalex Faspro survival data rest on a relative survival mixture cure model (MCM) built from actual progression-free survival and overall survival results in the trial. Statisticians estimated that approximately 87% of patients treated with Tec-Dara may experience a mortality risk and projected life expectancy similar to an age-matched general population. Best-fit modeling put the overall survival “cure fraction” at 86.6% (95% CI, 81–91) for the combination, compared with 0% (95% CI, 0–53) for the study’s standard-of-care (SOC) comparator, daratumumab subcutaneous plus dexamethasone with either pomalidomide or bortezomib (DPd/DVd). Projected remaining life expectancy came out to 18.5 years for Tec-Dara patients versus 4.9 years for the SOC arm, against an estimated 21.1 years for the matched general population — a gap that puts the scale of the J&J Tecvayli Darzalex Faspro survival advantage into perspective. The MCM was applied to 291 patients who received TECVAYLI plus DARZALEX FASPRO and 296 patients treated with DPd/DVd, with the company noting substantially greater statistical uncertainty around the SOC estimates.

Johnson & Johnson said the J&J Tecvayli Darzalex Faspro survival modeling is intended to illustrate how far treatment choice at first relapse might move the needle on lifetime outcomes, not to replace the trial’s maturing survival data. Dr. Luciano J. Costa, Professor of Multiple Myeloma and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama at Birmingham, said the findings show how consequential treatment choice at first relapse can be, calling the effect “consequential in shaping a patient’s long-term trajectory.” Dr. Costa, a paid J&J consultant who was not compensated for this media commentary, added that the sustained disease control observed with the combination is shifting expectations in RRMM beyond simply delaying the next relapse toward the possibility of durable, long-term disease control.

J&J TECVAYLI DARZALEX FASPRO Survival Data Show a 90% Drop in Progression Risk

A separate, post hoc competing-risk analysis of MajesTEC-3 offers a mechanistic explanation for the J&J Tecvayli Darzalex Faspro survival benefit. At 36 months, the cumulative incidence of disease progression was 8.7% with TECVAYLI plus DARZALEX FASPRO versus 62.1% with DPd/DVd, a 90% relative reduction in progression risk (subdistribution hazard ratio [sHR] = 0.10; 95% CI, 0.07–0.16; P<0.0001). The 36-month overall survival rate was 83.3% for the combination versus 65.0% for SOC (hazard ratio [HR] = 0.46; 95% CI, 0.32–0.65; P<0.0001). Critically, non-relapse mortality stayed similar between arms, 10.2% with Tec-Dara versus 9.0% with DPd/DVd (sHR = 1.16; 95% CI, 0.69–1.98; P=0.5668). indicating the survival gap is being driven by disease control rather than added treatment-related risk.

Learn More

Gilead Accelerates Global Access Strategy for Gilead Once-Yearly Lenacapavir in HIV Prevention Push

The timing behind the J&J Tecvayli Darzalex Faspro survival advantage is notable. There was no measurable overall-survival difference between arms through the first 10 months of treatment (HR = 1.08; 95% CI, 0.64–1.81). Beyond 10 months, however, outcomes diverged sharply in favor of TECVAYLI plus DARZALEX FASPRO, with a 78% reduction in the risk of death relative to DPd/DVd (HR = 0.22; 95% CI, 0.13–0.38). A prespecified restricted mean survival time analysis confirmed a statistically significant overall-survival benefit, with a difference of 2.15 months (P=0.0088). Together with the mixture cure model, J&J said the competing-risk data build a complementary case: one shows the potential ceiling on long-term disease control, the other explains the mechanism behind it.

J&J TECVAYLI DARZALEX FASPRO Survival Benefit Builds on a Broader Myeloma Portfolio

Company leadership framed the J&J Tecvayli Darzalex Faspro survival analyses as part of a larger ambition to change what is achievable in multiple myeloma. Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine, said the ongoing MajesTEC-3 analyses “challenge long-held expectations of what may be possible,” adding that the company’s ambition is ultimately to stop defining multiple myeloma as incurable. Johnson & Johnson describes its multiple myeloma franchise, see the Johnson & Johnson company profile for the full portfolio breakdown, as spanning CD38-directed therapies, BCMA- and GPRC5D-targeting bispecific antibodies, and cellular therapies, positioning TECVAYLI and DARZALEX FASPRO alongside CARVYKTI and TALVEY in a portfolio the company says has helped extend survival in myeloma from a few years to a decade or more over the past ten years.

MajesTEC-3 (NCT05083169) is an ongoing, randomized Phase 3 study comparing TECVAYLI plus subcutaneous daratumumab against investigator’s choice of daratumumab SC combined with dexamethasone and either pomalidomide or bortezomib, in patients with RRMM who received one to three prior lines of therapy. The trial’s primary endpoint is progression-free survival, with secondary endpoints spanning complete response or better, overall response rate, minimal residual disease negativity (10⁻⁵ by next-generation sequencing), overall survival, time to symptom worsening, and safety. Both new analyses underpinning the J&J Tecvayli Darzalex Faspro survival story, the mixture cure model (Effelterre et al.) and the post hoc survival and progression analysis (Costa et al.), were presented as oral sessions at IMS under abstracts OA-49 and OA-58.

Regulatory Momentum Widens Access to the J&J TECVAYLI DARZALEX FASPRO Survival Combination

The new J&J Tecvayli Darzalex Faspro survival data land against a fast-moving regulatory backdrop. Building toward today’s J&J Tecvayli Darzalex Faspro survival data, the U.S. FDA approved TECVAYLI in combination with DARZALEX FASPRO in March 2026 for adults with RRMM who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, a filing that was proactively selected for the Commissioner’s National Priority Voucher Pilot Program and also received Breakthrough Therapy Designation and Real-Time Oncology Review. In August 2026, the European Commission followed with an indication extension for TECVAYLI plus daratumumab in adults with RRMM who have received at least one prior therapy, likewise opening use as early as second line.

Learn More

TEZSPIRE Eosinophilic Esophagitis Trial: Amgen, AstraZeneca Report Positive Phase 3 CROSSING Results

TECVAYLI itself first reached patients through accelerated FDA approval in October 2022 as a monotherapy for heavily pretreated RRMM, and the European Commission granted conditional marketing authorization the same year. More than 30,000 patients have now been treated with TECVAYLI worldwide, a base that Johnson & Johnson expects to expand further as the J&J Tecvayli Darzalex Faspro survival data reach treating physicians.

MajesTEC-3 Mixture Cure Model: Projected Long-Term Outcomes

MajesTEC-3 Post Hoc Analysis: 36-Month Outcomes

Overall Survival by Follow-Up Period

Regulatory and Development Timeline